Pharming Group Reports Third-Quarter 2026 Financial Results
Pharming Group reported preliminary, unaudited financial results for the three months ended September 30, 2026. The headline also cites strong revenue growth, Joenja APDS expansion and CVID topline data expected in November.
Leiden, the Netherlands, October 27, 2026: Pharming Group N.V. (Euronext Amsterdam: PHARM/NASDAQ:PHAR), a global biotechnology company focused on rare immune and genetic diseases, presents its preliminary (unaudited) financial report for the three months ended September 30, 2026.Interim Co-Chief Ex…